Merck's (MRK -2.9%) Tredaptive (Cordaptive) cholesterol treatment failed to meet its primary...

Merck's (MRK -2.9%) Tredaptive (Cordaptive) cholesterol treatment failed to meet its primary goal in a massive study of 25,673 patients. The drug didn't significantly cut the risk of coronary deaths, non-fatal heart attacks, strokes or revascularizations compared with statin therapy. Merck will end its bid to for regulatory approval of Tredaptive in the U.S.; the drug is sold in 40 countries and had sales of $13M in Q1-Q3. (PR)

From other sites
Comments (1)
  • biochemist
    , contributor
    Comments (797) | Send Message
    Of course we'll need to see the final results (probably to be presented at ACC in March 2013), but this probably means the end of the line for niacin treatment for dyslipidemia and maybe also for HDL-C-raising therapies in general. This result likely validates the AIM HIGH result and may also validate the decisions by other pharmas to discontinue CETP inhibitor (HDL-C-raising) programs.
    20 Dec 2012, 04:32 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs